Hello profits. Did anyone honestly think 23andMe was going to stick to selling $100 DNA kits? The company is still in regulatory talks with the FDA, but in the meantime has found a sustainable business model. 23andMe announced a $60 million deal with Genentech to provide aggregate genetic data for Parkinson’s research.
On the surface, you may have the reaction of: ‘I can’t believe they are selling medical data.’ That’s understandable, but think of it like this. 23andMe is a small company, backed by Yuri Milner and Google Ventures. All that data would be sitting in storage if they don’t deal or open it up for scien...
Also read: SMILE Inc. on the App Store